Navigation Links
Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
Date:7/18/2012

SEATTLE, July 18, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported that OMS824, the lead compound in the Company's phosphodiesterase 10 (PDE10) program for schizophrenia, has successfully completed all of the preclinical studies that Omeros expects will be necessary for the drug's planned Investigational New Drug Application (IND). OMS824 selectively inhibits PDE10, which is an enzyme expressed in areas of the brain linked to diseases that affect cognition, including schizophrenia and Huntington's disease. 

With these positive preclinical data, Omeros confirmed with the U.S. Food and Drug Administration (FDA) the Company's intent to submit an IND for OMS824 during the current quarter.  Following IND submission, Omeros is required to wait 30 days before enrolling patients into clinical trials to allow the FDA to review the IND to assure that OMS824 will not subject clinical trial patients to unreasonable risks. Omeros believes that the findings observed in the preclinical toxicology studies of OMS824 do not suggest any unreasonable safety risk to humans. Accordingly, the Company is preparing to begin enrolling patients in a Phase 1 dose-ranging clinical trial following the end of the required 30-day waiting period.

"Omeros' PDE10 program is on track to report Phase 1 clinical trial data this year," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "Our two Phase 3 programs also remain on schedule, and we expect to read out data later this year from our ongoing trials evaluating OMS302 in lens replacement surgery and OMS103HP in arthroscopic meniscectomy procedures. We have already begun building the NDA for OMS302, which we plan to submit early next year. Our other programs are also advancing nicely, and we anticipate that a number of them will be ready to enter the clinic next year as well."

Abo
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
2. Omeros Prices $30 Million Public Offering of Common Stock
3. Omeros Announces Proposed Public Offering of Common Stock
4. Omeros to Present at Jefferies 2012 Global Healthcare Conference
5. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
6. Omeros to Present at Deutsche Bank Securities Health Care Conference
7. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
8. Mindray Medical Completes Acquisition of Dragonbios Orthopedics Business
9. Henry Schein Completes Three Acquisitions To Advance Strategic Plan
10. SJF Ventures Completes Oversubscribed Series A Round for BioSurplus
11. Terumo Completes U.S. Patient Enrollment in the OSPREY Trial to Evaluate the MISAGO Self-expanding Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Amgen (NASDAQ: ... th Annual  Healthcare Conference on Thursday, May 30, 2013, ... , beginning at 9:20 a.m. Eastern Daylight Time. ... Amgen, will present at the conference. Live audio of the ... website, www.amgen.com , under Investors. A replay of the ...
(Date:5/23/2013)... 23, 2013  MGC Diagnostics Corporation (NASDAQ: ... company, today scheduled a conference call to discuss its ... 2013, ended April 30, 2013. The call will be ... The Company will report financial results for the second ... on Thursday, May 30, 2013. (Logo: ...
(Date:5/23/2013)... , May 23, 2013 More than ... may not benefit from chemotherapy and still have excellent ... launch of one of the largest sources of online ... website and interactive Facebook page provide recently diagnosed women ... can safely avoid chemotherapy. "We anticipate these ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3
... Nov. 4, 2010 Decision Resources, one of the ... healthcare issues, finds that biosimilar erosion of branded erythropoietin ... more rapid and more complete in the United States ... ESAs entered the European market in 2007. According to ...
... 4, 2010 NuView Life Sciences, Inc ("NuView"), ... proprietary target specific biomarkers for utilization with Positron ... its applications for the Qualifying Therapeutic Discovery Project ... The grants totaling just over $1.2 million dollars ...
Cached Medicine Technology:Biosimilar Erosion of Branded ESA Market Share Will be More Rapid in the U.S. Than in Europe 2NuView Life Sciences Awarded Grants Under the Patient Protection and Affordable Care Act of 2010 2
(Date:5/24/2013)... Coral Springs, FL (PRWEB) May 24, 2013 ... to present May air dates for Charlotte, North Carolina. It ... home to many Fortune 500 companies. The city is populated ... top-notch healthcare organizations which cover residents in both North and ... program about all things medically-related can tune into WAXN-TV 64 ...
(Date:5/24/2013)... GA (PRWEB) May 24, 2013 CBT News.com ... Sales. Gonter joins the web-based retail automotive industry news organization ... , “I’m excited to join a group that’s so ... perfect example of how online video content is on the ... in the motorcycle business and segued into advertising at Cycle ...
(Date:5/24/2013)... Electric™ Energy Straws, an exciting new brand of ... and will be the lead sponsor on Munoz’s Chevy #26 ... Speedway. Munoz, who is part of Andretti Autosports’ fantastic five ... race, qualifying to be named the 2013 Indy 500 Fastest ... race. , While Munoz is grabbing headlines around the ...
(Date:5/24/2013)... American International College of Arts and ... agreement with Old Dominion University (ODU) that ... , The program will permit ODU students ... cell biology course, taught by AICASA’s faculty, for three ... of Antigua (AUA) College of Medicine , students will ...
(Date:5/24/2013)... Texas (PRWEB) May 24, 2013 ... range of products used outside the central laboratory, ... by a healthcare practitioner or by consumers. This ... coagulation, fertility and pregnancy, infectious and cardiovascular disease ... areas such as critical care, surgical and emergency ...
Breaking Medicine News(10 mins):Health News:Health Briefs TV Presents May Air Dates for Charlotte, North Carolina 2Health News:Unistraw Electric™ Energy Straw Chevy Car Powers Indianapolis 500 Rookie Driver Carlos Munoz 2Health News:Unistraw Electric™ Energy Straw Chevy Car Powers Indianapolis 500 Rookie Driver Carlos Munoz 3Health News:AICASA Signs Articulation Agreement with Old Dominion University to Create Study Abroad Program 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 3
... Practice Manager Notes Ease of Use, Time Savings, ... Healthcare, Inc. has,announced that West Michigan Orthopaedics, a ... is moving to the Intergy by Sage,practice management ... The three-physician group had been on The ...
... PARK, N.C., Dec. 11 Quintiles,Transnational Corp. today ... President and General Counsel., Previously Senior Vice ... Quintiles in 1998 as Vice President, European,Legal Affairs., ... and the clinical,research industry, having served the company ...
... Influenza Vaccination Into the New Year, BETHESDA, ... season,in full swing, getting vaccinated against influenza, commonly ... keep you and your family healthy. Too many,people ... in October and,November, but the National Foundation for ...
... Dec. 11 Amedica Corporation, an,orthopedic implants company ... the U.S. Food and Drug Administration,has granted a ... spinal implant., The Valeo VBR spinal implant ... surgical correction and stabilization of the thoracolumbar spine.,The ...
... Advance(R) and Similac(R) Isomil(R) Advance(R) Formulas Now ... Available in Nipple-Ready 8-Fluid-Ounce Bottles, COLUMBUS, Ohio, Dec. ... moms commissioned by Abbott,s Similac brand, packing the,diaper bag ... 30 minutes.,Nearly all moms surveyed (98 percent) agree that ...
... cells (progenitor cells) to treat the damage to cardiac ... Emory University School of Medicine. , The study investigators--Emory ... update their colleagues on its progress at the American ... "This is one of the first trials where patients ...
Cached Medicine News:Health News:West Michigan Orthopaedics Migrates to Intergy by Sage Practice Management System 2Health News:West Michigan Orthopaedics Migrates to Intergy by Sage Practice Management System 3Health News:Don't Let Influenza Ruin Your Holidays - Get Vaccinated 2Health News:Don't Let Influenza Ruin Your Holidays - Get Vaccinated 3Health News:Amedica Receives FDA Special 510(k) Clearance for its Valeo(TM) Ceramic Spinal Implant 2Health News:Similac(R) Survey Finds New Moms Want Convenient, Time-Saving Baby Products 2Health News:Similac(R) Survey Finds New Moms Want Convenient, Time-Saving Baby Products 3Health News:Adult stem cell heart attack study updated at American Society for Hematology Meeting 2
... H-1200 Fast Flow Fluid Warmer, a new generation ... the existing Level 1 Fast Flow Fluid Warmer ... Fluid Warmer incorporates the features of integrated air ... deliver warm fluids as fast as 1,000 ml/minute ...
Futuremeds Astotherm Plus Blood and Fluid Warmers meet American Blood Bank and ECRI standards., ,Astotherm is a durable warmer you can rely on for many years....
... Flexible excellence for patients and clinicians., ... the Aestiva/5 anesthesia system, the Aestiva/5 MRI ... anesthesia systems with a fully functional, integrated ... (300 Gauss, 1.5 T active shielded magnet), ...
... meeting today's and tomorrow's needs in anesthesia procedures., ... solutions in its field today. This compact system ... revolving arm holds the complete user interface. A ... that there is less need to move the ...
Medicine Products: